keine Finanzberatung

ABBV · AbbVie Inc.

Pharma giant behind Humira's successors Skyrizi and Rinvoq

Risiko 4/10 · LOW-MODERATE RISK · pharma pivot · $256.46 ▼ 1.44%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $256.46
  • Market cap $453.2B
  • P/E (ttm) 72.45
  • Div yield 2.70%
  • 52-wk range $190.75 – $267.47
  • Index rank #24 / —

Wichtigste Risiken

  • Concentration in Skyrizi/Rinvoq and their eventual patent cliffs (Shareholders) — HIGH
  • US drug-price negotiation and pricing politics (Shareholders) — MED
  • Pipeline and M&A must keep refilling the growth engine (Shareholders) — MED
  • Biosimilar erosion of the legacy portfolio (Shareholders) — MED

Fazit

Reasonable hold if you trust the two-drug growth engine; the cheap forward multiple prices in some of the doubt.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.